TRIAZOLONE COMPOUNDS AND USES THEREOF
The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.
1 .- 32 . (canceled)
33 . A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
34 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
35 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
36 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
37 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
38 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
39 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
40 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
41 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
42 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
43 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
44 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
45 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
46 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
47 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
48 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
49 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
50 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
51 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
52 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
53 . The compound of claim 33 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
54 . A pharmaceutical composition comprising the compound of claim 33 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.